Clinical trial
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
NCT00032292 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00032292 |
|---|---|
| Title | Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease |
| Official title | A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation |
| Lead sponsor | Facet Biotech, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease |
| Intervention type | Drug |
| Interventions | Visilizumab |
| Enrollment | 34 |
| Start date | Mar 1, 2002 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Mar 18, 2002 |
| Last update posted | Mar 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: